Articles tagged with: Filanesib
News»

This year’s meeting of the American Society of Hematology (ASH) was held December 8 through 11 in Atlanta.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting. After the meeting concluded, The Beacon began publishing in-depth articles about the key research findings.
This article, however, shifts the focus to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did the research …
News»

ARRY-520 is one of several potential new anti-myeloma agents that was highlighted at the American Society of Hematology (ASH) annual meeting earlier this week.
Initial results from two clinical trials show promise for ARRY-520 (filanesib), alone or in combination with other myeloma drugs, as a therapeutic option for heavily pretreated multiple myeloma patients.
“ARRY-520 shows promising activity in combination with dexamethasone in heavily pretreated myeloma patients,” said Dr. Jatin Shah, from the MD Anderson Cancer Center in Houston and lead investigator of both studies.
Based on their findings, the study investigators …
News»

Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.
It also was the busiest day of the meeting in regard to myeloma-related research.
The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall. More than a hundred of the posters reported on the results of myeloma-related research.
Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development. They may involve laboratory research, clinical …
News»

This year’s American Society of Hematology (ASH) meeting continues in Atlanta. Yesterday was the third day of the meeting and the busiest day in terms of myeloma-related presentations. It was packed full of both oral and poster presentations.
There were so many myeloma-related talks given yesterday that many of them were held simultaneously. The Beacon will therefore summarize presentations from the four most important sessions in updates such as this one.
This update covers presentations from the second of the four key oral presentation sessions. An update published yesterday covers presentations from …
News»

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clinical trials involving a number of potential new drugs under development for the treatment of multiple myeloma.
In particular, results for newer, lesser known agents that are in the early stages of clinical development will take center stage. These agents include ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.
According to the recently …
News»

Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.
Predicting Response To Immunomodulatory Drugs
During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma. Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide. Another study (abstract) …
News»

Yesterday was the first day of the American Society of Hematology (ASH) 2011 annual meeting, which is being held in San Diego.
Although the day featured no oral presentations of new myeloma-related research, it started with an interesting educational session focused on multiple myeloma.
There also were a number of poster presentations during the day summarizing important new research findings.
The educational session in the morning featured three presentations by leading myeloma specialists.
Induction Therapy And Maintenance Treatment
The first presentation was by Dr. Donna Reece of the Princess Margaret Hospital in …